JPRN-UMIN000017912已完成未知
Combined use of long-acting insulin analogue, GLP-1 receptor agonist, and sulfonylurea in type 2 diabetes - Combined use of long-acting insulin analogue, GLP-1 receptor agonist, and sulfonylurea in type 2 diabetes
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •- Patients with severe hepatic, renal, and/or cardiac disease - Patients with hypersentitivity to the agents used in the current study - Patients who are pregnant, breast-feeding or may become pregnant - Patients who are judged by the investigator to be inappropriate for this study for any other reason.
研究者
相似试验
进行中（未招募）
不适用
Tratamiento combinado de insulina glargina y sitagliptina en pacientes con diabetes tipo 2 no controlados suficientemente con un tratamiento previo con metformina y con insulina glargina o sitagliptina (Extensión del estudio LANTU_C_02761). - EXT_EASIEDiabetes tipo 2 tratada con metformina pero no suficientemente controlada con unt tratamiento previo de metformina y con insulina glargina o sitagliptina.MedDRA version: 9.1Level: LLTClassification code 10053247Term: Insulin-requiring type 2 diabetes mellitusEUCTR2008-000521-19-ESsanofi aventis Groupe265
进行中（未招募）
不适用
Combination therapy of insulin glargine and sitagliptin in patients with type 2 diabetes not adequately controlled by a previous treatment with metformin and either insulin glargine or sitagliptin (Extension of the study LANTU_C_02761). - EXT_EASIEType 2 diabetes treated with metformin and not adequately controlled by a previous treatment with metformin and either insulin glargine or sitagliptinMedDRA version: 9.1Level: LLTClassification code 10053247Term: Insulin-requiring type 2 diabetes mellitusEUCTR2008-000521-19-PTsanofi aventis Groupe265
进行中（未招募）
不适用
Combination therapy of insulin glargine and sitagliptin in patients with type 2 diabetes not adequately controlled by a previous treatment with metformin and either insulin glargine or sitagliptin (Extension of the study LANTU_C_02761). - EXT_EASIEEUCTR2008-000521-19-ATsanofi aventis Groupe265
进行中（未招募）
不适用
Combination therapy of insulin glargine and sitagliptin in patients with type 2 diabetes not adequately controlled by a previous treatment with metformin and either insulin glargine or sitagliptin (Extension of the study LANTU_C_02761). - EXT_EASIEType 2 diabetes treated with metformin and not adequately controlled by a previous treatment with metformin and either insulin glargine or sitagliptinMedDRA version: 9.1Level: LLTClassification code 10053247Term: Insulin-requiring type 2 diabetes mellitusEUCTR2008-000521-19-NLsanofi aventis Groupe265
进行中（未招募）
1 期
Combination therapy of insulin glargine and sitagliptin in patients with type 2 diabetes not adequately controlled by a previous treatment with metformin and either insulin glargine or sitagliptin (Extension of the study LANTU_C_02761). - EXT_EASIEType 2 diabetes treated with metformin and not adequately controlled by a previous treatment with metformin and either insulin glargine or sitagliptinMedDRA version: 9.1 Level: LLT Classification code 10053247 Term: Insulin-requiring type 2 diabetes mellitusEUCTR2008-000521-19-GBsanofi aventis Groupe265